Glenmark Pharmaceuticals on Friday said its US-based unit is gearing up to introduce a generic sodium phosphates injection in the American market.
The Mumbai-based drug firm said its product is therapeutically equivalent to Hosira Inc’s reference listed drug.
Glenmark will begin distribution of the injection in the US market in April 2026, it said in a regulatory filing.
According to IQVIA, sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP single-dose vials saw annual sales of around USD 66.8 million.
Shares of the company were trading 0.82 per cent up at Rs 2,144.50 apiece on BSE.​Glenmark Pharmaceuticals on Friday said its US-based unit is gearing up to introduce a generic sodium phosphates injection in the American market.
The Mumbai-based drug firm said its product is therapeutically equivalent to Hosira Inc’s reference listed drug.
Glenmark will begin distribution of the injection in the US market in April 2026, it said in a regulatory filing.
According to IQVIA, sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP single-dose vials saw annual sales of around USD 66.8 million.
Shares of the company were trading 0.82 per cent up at Rs 2,144.50 apiece on BSE. ​Latest News [ SOBAN NEWS: International and National ]
